Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe.

IF 1.6 4区医学 Q4 INFECTIOUS DISEASES

Southern African Journal of Hiv Medicine Pub Date : 2022-01-01 DOI:10.4102/sajhivmed.v23i1.1435

Linda A Mandikiyana Chirimuta, Margaret J Pascoe, Sara Lowe

引用次数: 2

Abstract

We report two cases of dolutegravir (DTG) resistance in highly treatment experienced patients. Monitoring for treatment failure and adherence support is important in highly treatment experienced patients taking DTG.

What this study adds: Dolutegravir is the mainstay of HIV treatment programmes and emergence of drug resistance to DTG is of public health relevance.

查看原文本刊更多论文

在integrase-naïve中出现的多替格拉韦耐药性，来自津巴布韦的治疗经历患者。

我们报告两例多替替韦(DTG)耐药的高度治疗经验的患者。监测治疗失败和依从性支持是重要的高度治疗经验的患者服用DTG。这项研究补充的内容:多替格拉韦是艾滋病毒治疗规划的支柱，对多替格拉韦的耐药性的出现与公共卫生有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Southern African Journal of Hiv Medicine 医学-病毒学

CiteScore

2.80

自引率

11.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.